Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 1
1967 2
1968 3
1970 2
1972 1
1973 1
1974 2
1975 2
1976 3
1977 4
1978 8
1979 4
1980 11
1981 7
1982 9
1983 30
1984 28
1985 31
1986 32
1987 42
1988 49
1989 75
1990 51
1991 50
1992 65
1993 57
1994 59
1995 81
1996 81
1997 84
1998 80
1999 88
2000 103
2001 110
2002 147
2003 199
2004 219
2005 213
2006 224
2007 246
2008 258
2009 230
2010 292
2011 305
2012 298
2013 365
2014 417
2015 437
2016 396
2017 375
2018 393
2019 282
2020 27
Text availability
Article attribute
Article type
Publication date

Search Results

5,893 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Cancer Cell Dormancy.
Recasens A, Munoz L. Recasens A, et al. Trends Pharmacol Sci. 2019 Feb;40(2):128-141. doi: 10.1016/j.tips.2018.12.004. Epub 2019 Jan 3. Trends Pharmacol Sci. 2019. PMID: 30612715 Review.
Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K, Tsai KK. Fitzgerald K, et al. Semin Cutan Med Surg. 2019 Mar 1;38(1):E67-E74. doi: 10.12788/j.sder.2019.010. Semin Cutan Med Surg. 2019. PMID: 31051028 Review.
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. Aghajanian C, et al. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. Gynecol Oncol. 2018. PMID: 29804638 Free PMC article. Clinical Trial.
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
How I treat first relapse of myeloma.
Harousseau JL, Attal M. Harousseau JL, et al. Blood. 2017 Aug 24;130(8):963-973. doi: 10.1182/blood-2017-03-726703. Epub 2017 Jul 5. Blood. 2017. PMID: 28679737 Review.
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A. Rosen VM, et al. Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246. doi: 10.1097/IGC.0000000000001000. Int J Gynecol Cancer. 2017. PMID: 28448304 Free PMC article. Review.
5,893 results
Jump to page
Feedback